Department of Digestive Surgery, Dupuytren University Hospital, Limoges, France; CNRS, XLIM, UMR, 7252, Limoges University, France; Université de Paris, CAP Paris-Tech, INSERM U1275, 49 Boulevard de La Chapelle, F-75475, Paris Cedex 10, France.
Université de Paris, CAP Paris-Tech, INSERM U1275, 49 Boulevard de La Chapelle, F-75475, Paris Cedex 10, France; Department of Oncologic and Digestive Surgery, AP-HP, Hospital Lariboisière, 2 rue Ambroise Paré, F-75475, Paris Cedex 10, France.
Surg Oncol. 2020 Jun;33:158-163. doi: 10.1016/j.suronc.2020.02.014. Epub 2020 Feb 15.
This study evaluated the histologic response after preoperative systemic therapy (pST) using the Peritoneal Regression Grading Score (PRGS) and tumor regression grade (TRG) classifications for patients with peritoneal metastases (PM) from colorectal cancer (CRC).
Twenty-three patients were selected from a prospective database of 196 patients who underwent CRS followed by HIPEC for synchronous PM from CRC. In all study patients, biopsies of the PM obtained before pST (during the first laparoscopy) and after pST (during cytoreductive surgery) were compared.
Complete (PRGS 1), Major (PRGS 2), Minor (PRGS 3) and no histological responses (PRGS 4) were obtained in 17,5%, 52% and 13% and 17,5% of patients, respectively. Major (TRG 1-2), partial (TRG3), and no (TRG4-5) histological tumor regression were observed in 61%, 9% and 30% of patients, respectively. Regardless of the classification applied, median OS was significantly higher in patients with a "complete or major" response than in those with a "minor/partial or no" response (54 vs. 26 months, p < 0.05).
The PRGS and TRG can be used in clinical practice to evaluate the histological response after pST. This study demonstrated that a complete histologic response of PM from CRC can be obtained after pST.
本研究评估了术前全身治疗(pST)后使用腹膜消退分级评分(PRGS)和肿瘤消退分级(TRG)分类的组织学反应,用于结直肠癌(CRC)腹膜转移(PM)患者。
从 196 例接受同步 CRC 腹膜转移 CRS 联合 HIPEC 治疗的前瞻性数据库中选择 23 例患者。在所有研究患者中,比较了 pST 前(第一次腹腔镜检查时)和 pST 后(细胞减灭性手术时)获得的 PM 活检。
17.5%、52%、13%和 17.5%的患者分别获得完全(PRGS 1)、主要(PRGS 2)、次要(PRGS 3)和无组织学反应(PRGS 4)。61%、9%和 30%的患者分别观察到主要(TRG 1-2)、部分(TRG3)和无(TRG4-5)组织学肿瘤消退。无论应用哪种分类,“完全或主要”反应患者的中位 OS 明显高于“次要/部分或无”反应患者(54 与 26 个月,p<0.05)。
PRGS 和 TRG 可用于临床实践中评估 pST 后的组织学反应。本研究表明,CRC 的 PM 经过 pST 后可获得完全的组织学反应。